WallStreetZenWallStreetZen

NYSE: PRGO
Perrigo Co PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PRGO

Based on 2 analysts offering 12 month price targets for Perrigo Co PLC

Min Forecast
$35.00+63.09%
Avg Forecast
$37.50+74.74%
Max Forecast
$40.00+86.39%

Should I buy or sell PRGO stock?

Based on 2 analysts offering ratings for Perrigo Co PLC.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their PRGO stock forecasts and price targets.

PRGO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-07
lockedlocked$00.00+00.00%2025-08-07

1 of 1

Forecast return on equity

Is PRGO forecast to generate an efficient return?

Company
N/A
Industry
29.5%
Market
-59.4%

Forecast return on assets

Is PRGO forecast to generate an efficient return on assets?

Company
N/A
Industry
14.19%

PRGO earnings per share forecast

What is PRGO's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$2.94
Avg 2 year Forecast
$3.11
Avg 3 year Forecast
$3.40

PRGO revenue forecast

What is PRGO's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$4.4B+1%
Avg 2 year Forecast
$4.4B+1.64%
Avg 3 year Forecast
$4.5B+4.09%
PRGO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PRGO revenue growth forecast

How is PRGO forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
1.25%
Industry
4.94%
Market
11.75%
PRGO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PRGO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PRGO vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
PRGO$21.46$37.50+74.74%Strong Buy
SUPN$52.83$62.67+18.62%Strong Buy
PBH$62.23$86.00+38.20%Strong Buy
INDV$25.13$27.33+8.77%Strong Buy
ALVO$8.40$14.00+66.67%Strong Buy
View Top Pharmaceutical Stocks

Perrigo Co Stock Forecast FAQ

Is Perrigo Co Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSE: PRGO) stock is to Strong Buy PRGO stock.

Out of 2 analysts, 2 (100%) are recommending PRGO as a Strong Buy, 0 (0%) are recommending PRGO as a Buy, 0 (0%) are recommending PRGO as a Hold, 0 (0%) are recommending PRGO as a Sell, and 0 (0%) are recommending PRGO as a Strong Sell.

If you're new to stock investing, here's how to buy Perrigo Co stock.

What is PRGO's earnings growth forecast for 2025-2027?

(NYSE: PRGO) Perrigo Co's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 23.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.09%.

Perrigo Co's earnings in 2025 is -$80,300,000.On average, 2 Wall Street analysts forecast PRGO's earnings for 2025 to be $404,493,473, with the lowest PRGO earnings forecast at $403,117,645, and the highest PRGO earnings forecast at $405,869,301. On average, 2 Wall Street analysts forecast PRGO's earnings for 2026 to be $427,882,552, with the lowest PRGO earnings forecast at $423,755,067, and the highest PRGO earnings forecast at $432,010,036.

In 2027, PRGO is forecast to generate $467,093,654 in earnings, with the lowest earnings forecast at $463,654,083 and the highest earnings forecast at $470,533,224.

What is PRGO's revenue growth forecast for 2025-2027?

(NYSE: PRGO) Perrigo Co's forecast annual revenue growth rate of 1.25% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.75%.

Perrigo Co's revenue in 2025 is $4,326,000,000.On average, 2 Wall Street analysts forecast PRGO's revenue for 2025 to be $601,157,099,148, with the lowest PRGO revenue forecast at $599,558,386,849, and the highest PRGO revenue forecast at $602,755,811,447. On average, 2 Wall Street analysts forecast PRGO's revenue for 2026 to be $604,946,129,845, with the lowest PRGO revenue forecast at $601,633,135,684, and the highest PRGO revenue forecast at $608,259,124,007.

In 2027, PRGO is forecast to generate $619,504,455,309 in revenue, with the lowest revenue forecast at $618,599,848,307 and the highest revenue forecast at $620,409,062,311.

What is PRGO's forecast return on assets (ROA) for 2025-2028?

(NYSE: PRGO) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 14.19%.

What is PRGO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year PRGO price target, the average PRGO price target is $37.50, with the highest PRGO stock price forecast at $40.00 and the lowest PRGO stock price forecast at $35.00.

On average, Wall Street analysts predict that Perrigo Co's share price could reach $37.50 by Aug 7, 2026. The average Perrigo Co stock price prediction forecasts a potential upside of 74.74% from the current PRGO share price of $21.46.

What is PRGO's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSE: PRGO) Perrigo Co's current Earnings Per Share (EPS) is -$0.58. On average, analysts forecast that PRGO's EPS will be $2.94 for 2025, with the lowest EPS forecast at $2.93, and the highest EPS forecast at $2.95. On average, analysts forecast that PRGO's EPS will be $3.11 for 2026, with the lowest EPS forecast at $3.08, and the highest EPS forecast at $3.14. In 2027, PRGO's EPS is forecast to hit $3.40 (min: $3.37, max: $3.42).

What is PRGO's forecast return on equity (ROE) for 2025-2028?

(NYSE: PRGO) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.